A 62-year-old German man got 217 Covid shots and was completely fine

A 62-year-old man in Germany decided to get 217 Covid-19 vaccinations over the course of 29 months for “personal reasons”. But, somewhat surprisingly, they do not seem to have suffered any ill effects from over-vaccination A newly published case study in Lancet Infectious Diseases,

Of course, this is just one individual case, so the findings can’t be extrapolated to the general population. But, they conflict with widely prevalent concerns among researchers that such excessive exposure to vaccination could lead to a weakened immune response. Some experts have raised concerns in the discussion about how often people should get COVID-19 booster doses.

In cases of repeated exposure to a disease-causing germ, “there is a signal that certain types of immune cells, called T-cells, become exhausted, causing them to release less anti-inflammatory messenger substances,” co-authors. According to lead study author Kilian Schauber from the Institute of Microbiology – Clinical Microbiology, Immunology and Hygiene. This, along with other effects, could lead to “immune tolerance” that leads to weaker responses that are less effective at fighting the pathogen, Schauber explained in a news release.

The German man’s history of over-vaccination appears to be a good case for seeing evidence of such tolerance and attenuated reactions. Schauber and his colleagues learned about the man’s case through news headlines – authorities had launched a fraud investigation against the man, who had confirmed 130 vaccinations in nine months, but never filed any criminal charges. Charges were not filed. “We then contacted him and invited him to undergo various tests in Erlangen (a city in Bavaria),” said Schöber. “He was very interested in doing this.” The person then reported an additional 87 vaccinations to researchers, a total of eight different vaccine formulations, including the updated booster.

Researchers were able to collect blood and saliva samples from the man during his 214th to 217th vaccine dose. They compared her immune responses to those of 29 people who received the standard three-dose series.

During an increasing number of vaccinations, the man never reported any side effects from the vaccine, and his clinical trials revealed no abnormalities related to hypervaccination. Researchers took a detailed look at their responses to the vaccines, finding that although some aspects of their protection were stronger, overall, their immune responses were functionally similar to those of people who had a much lower dose. Vaccine-induced antibody levels in their blood increased after the new dose, but then began to decline, as was seen in controls.

The ability of their antibodies to neutralize SARS-CoV-2 appeared to be five times to 11 times greater than that of controls, but the researchers noted that this was due to greater amounts of antibodies, not more powerful antibodies. Specific subsets of immune cells, namely B-cells trained against the spike protein of SARS-CoV-2 and T effector cells, were elevated compared to controls. But they appeared to be functioning normally. As another type of control, the researchers also looked at the person’s immune response to an unrelated virus, Epstein-Barr, which causes mononucleosis. They found that inactivated vaccination did not negatively impact responses to that virus, suggesting that it generally had no adverse effects on immune responses.

Ultimately, a variety of tests indicated that the man had never been infected with SARS-CoV-2. But the researchers were careful to note that this could be due to other precautions that person 217 took after receiving the vaccine.

“In summary, our case report shows that SARS-CoV-2 hypervaccination did not cause adverse events and increased the amount of spike-specific antibodies and T cells without having strong positive or negative effects on the intrinsic quality of adaptive immune responses ” “The authors concluded. “Importantly,” they said, “we do not support hypervaccination as a strategy to enhance adaptive immunity.”

This story was originally published on Ars Technica,

Leave a Reply

Your email address will not be published. Required fields are marked *

Discover more from news24alerts

Subscribe now to keep reading and get access to the full archive.

Continue reading